RecruitingNot ApplicableNCT06461962

Rural Community Peer Partnerships for Improving Methamphetamine-Associated Heart Failure Screening and Engagement


Sponsor

Oregon Health and Science University

Enrollment

200 participants

Start Date

Aug 19, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of PEER-Heart is to implement and assess feasibility and preliminary effectiveness of a community peer-facilitated screening for methamphetamine-associated heart failure (MAHF) and linkage to evidence-based cardiology care for people who use methamphetamine in rural areas.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Patient-defined regular use of methamphetamine in the last year
  • Any methamphetamine use in the past 30 days
  • Age 18 years or older
  • No client-reported diagnosis of heart failure
  • Able to communicate in English
  • Screen positive for potential methamphetamine-associated heart failure (MAHF) defined as B type natriuretic peptide (BNP) ≥50 pg/ml, or QRS width ≥120ms, or presence of any clinical heart failure symptoms

Exclusion Criteria2

  • Self-reported engagement in medical care for heart failure in past 6 months.
  • Actively taking medications for heart failure.

Interventions

OTHERTreatment as Usual

Peer-facilitated referral to a local primary care provider to follow-up their screening results.

OTHERTelehealth-Cardiology

Peer-facilitated virtual consultation with cardiovascular specialist, for follow-up of their screening results. Activities may include: referral for a locally performed testing including echocardiogram and additional blood work, and transitional care management facilitated by a remote nurse care manager and the peer Referral for a locally performed testing including echocardiogram Transitional care management facilitated by a remote nurse care manager and the peer


Locations(1)

Oregon Health & Science University

Portland, Oregon, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06461962


Related Trials